Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial.

Boxer AL, Qureshi I, Ahlijanian M, Grundman M, Golbe LI, Litvan I, Honig LS, Tuite P, McFarland NR, O'Suilleabhain P, Xie T, Tirucherai GS, Bechtold C, Bordelon Y, Geldmacher DS, Grossman M, Isaacson S, Zesiewicz T, Olsson T, Muralidharan KK, Graham DL, O'Gorman J, Haeberlein SB, Dam T.

Lancet Neurol. 2019 Jun;18(6):549-558. doi: 10.1016/S1474-4422(19)30139-5.

PMID:
31122495
2.

How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy.

Grimm MJ, Respondek G, Stamelou M, Arzberger T, Ferguson L, Gelpi E, Giese A, Grossman M, Irwin DJ, Pantelyat A, Rajput A, Roeber S, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Colosimo C, van Eimeren T, Kassubek J, Levin J, Meissner WG, Nilsson C, Oertel WH, Piot I, Poewe W, Wenning GK, Boxer A, Golbe LI, Josephs KA, Litvan I, Morris HR, Whitwell JL, Compta Y, Corvol JC, Lang AE, Rowe JB, Höglinger GU; Movement Disorder Society-endorsed PSP Study Group.

Mov Disord. 2019 Mar 18. doi: 10.1002/mds.27666. [Epub ahead of print]

PMID:
30884545
3.

Is the Latency from Progressive Supranuclear Palsy Onset to Diagnosis Improving?

Mamarabadi M, Razjouyan H, Golbe LI.

Mov Disord Clin Pract. 2018 Nov 8;5(6):603-606. doi: 10.1002/mdc3.12678. eCollection 2018 Nov-Dec.

PMID:
30637280
4.

Life expectancy in Parkinson disease.

Golbe LI, Leyton CE.

Neurology. 2018 Nov 27;91(22):991-992. doi: 10.1212/WNL.0000000000006560. Epub 2018 Oct 31. No abstract available.

PMID:
30381371
5.

Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.

Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Höglinger GU.

Lancet Neurol. 2017 Jul;16(7):552-563. doi: 10.1016/S1474-4422(17)30157-6. Epub 2017 Jun 13. Review.

6.

Which ante mortem clinical features predict progressive supranuclear palsy pathology?

Respondek G, Kurz C, Arzberger T, Compta Y, Englund E, Ferguson LW, Gelpi E, Giese A, Irwin DJ, Meissner WG, Nilsson C, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Whitwell JL, Antonini A, Bhatia KP, Bordelon Y, Corvol JC, Colosimo C, Dodel R, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris H, Nestor P, Oertel WH, Rabinovici GD, Rowe JB, van Eimeren T, Wenning GK, Boxer A, Golbe LI, Litvan I, Stamelou M, Höglinger GU; Movement Disorder Society-Endorsed PSP Study Group.

Mov Disord. 2017 Jul;32(7):995-1005. doi: 10.1002/mds.27034. Epub 2017 May 13. Review.

7.

Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?

Whitwell JL, Höglinger GU, Antonini A, Bordelon Y, Boxer AL, Colosimo C, van Eimeren T, Golbe LI, Kassubek J, Kurz C, Litvan I, Pantelyat A, Rabinovici G, Respondek G, Rominger A, Rowe JB, Stamelou M, Josephs KA; Movement Disorder Society-endorsed PSP Study Group.

Mov Disord. 2017 Jul;32(7):955-971. doi: 10.1002/mds.27038. Epub 2017 May 13. Review.

8.

Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I; Movement Disorder Society-endorsed PSP Study Group.

Mov Disord. 2017 Jun;32(6):853-864. doi: 10.1002/mds.26987. Epub 2017 May 3.

9.

Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration.

Sanchez-Contreras M, Heckman MG, Tacik P, Diehl N, Brown PH, Soto-Ortolaza AI, Christopher EA, Walton RL, Ross OA, Golbe LI, Graff-Radford N, Wszolek ZK, Dickson DW, Rademakers R.

Mov Disord. 2017 Jan;32(1):115-123. doi: 10.1002/mds.26815. Epub 2016 Oct 6.

10.

A geographical cluster of progressive supranuclear palsy in northern France.

Caparros-Lefebvre D, Golbe LI, Deramecourt V, Maurage CA, Huin V, Buée-Scherrer V, Obriot H, Sablonnière B, Caparros F, Buée L, Lees AJ.

Neurology. 2015 Oct 13;85(15):1293-300. doi: 10.1212/WNL.0000000000001997. Epub 2015 Sep 9.

11.

Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy.

Kouri N, Ross OA, Dombroski B, Younkin CS, Serie DJ, Soto-Ortolaza A, Baker M, Finch NCA, Yoon H, Kim J, Fujioka S, McLean CA, Ghetti B, Spina S, Cantwell LB, Farlow MR, Grafman J, Huey ED, Ryung Han M, Beecher S, Geller ET, Kretzschmar HA, Roeber S, Gearing M, Juncos JL, Vonsattel JPG, Van Deerlin VM, Grossman M, Hurtig HI, Gross RG, Arnold SE, Trojanowski JQ, Lee VM, Wenning GK, White CL, Höglinger GU, Müller U, Devlin B, Golbe LI, Crook J, Parisi JE, Boeve BF, Josephs KA, Wszolek ZK, Uitti RJ, Graff-Radford NR, Litvan I, Younkin SG, Wang LS, Ertekin-Taner N, Rademakers R, Hakonarsen H, Schellenberg GD, Dickson DW.

Nat Commun. 2015 Jun 16;6:7247. doi: 10.1038/ncomms8247.

12.

Scales to Assess Clinical Features of Progressive Supranuclear Palsy: MDS Task Force Report.

Hall DA, Forjaz MJ, Golbe LI, Litvan I, Payan CAM, Goetz CG, Leentjens AFG, Martinez-Martin P, Traon AP, Sampaio C, Post B, Stebbins G, Weintraub D, Schrag A.

Mov Disord Clin Pract. 2015 May 22;2(2):127-134. doi: 10.1002/mdc3.12130. eCollection 2015 Jun. Review. No abstract available.

13.

Progressive supranuclear palsy.

Golbe LI.

Semin Neurol. 2014 Apr;34(2):151-9. doi: 10.1055/s-0034-1381736. Epub 2014 Jun 25. Review.

PMID:
24963674
14.

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.

Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, Roberson ED, Höglinger GU, Koestler M, Jack CR Jr, Van Deerlin V, Randolph C, Lobach IV, Heuer HW, Gozes I, Parker L, Whitaker S, Hirman J, Stewart AJ, Gold M, Morimoto BH; AL-108-231 Investigators.

Lancet Neurol. 2014 Jul;13(7):676-85. doi: 10.1016/S1474-4422(14)70088-2. Epub 2014 May 27.

15.

The tau of PSP: a long road to treatment.

Golbe LI.

Mov Disord. 2014 Apr;29(4):431-4. doi: 10.1002/mds.25855. Epub 2014 Mar 1. No abstract available.

PMID:
24585428
16.

Diversity of pathological features other than Lewy bodies in familial Parkinson's disease due to SNCA mutations.

Fujishiro H, Imamura AY, Lin WL, Uchikado H, Mark MH, Golbe LI, Markopoulou K, Wszolek ZK, Dickson DW.

Am J Neurodegener Dis. 2013 Nov 29;2(4):266-75. eCollection 2013.

17.

Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations.

Soldner F, Laganière J, Cheng AW, Hockemeyer D, Gao Q, Alagappan R, Khurana V, Golbe LI, Myers RH, Lindquist S, Zhang L, Guschin D, Fong LK, Vu BJ, Meng X, Urnov FD, Rebar EJ, Gregory PD, Zhang HS, Jaenisch R.

Cell. 2011 Jul 22;146(2):318-31. doi: 10.1016/j.cell.2011.06.019. Epub 2011 Jul 14. Erratum in: Cell. 2011 Aug 19;146(4):659.

18.

Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy.

Höglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovcova J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P; PSP Genetics Study Group, Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton AB, Farrer MJ, Yu CE, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Müller U, Schellenberg GD.

Nat Genet. 2011 Jun 19;43(7):699-705. doi: 10.1038/ng.859.

19.

Movement disorders and pregnancy: a review of the literature.

Kranick SM, Mowry EM, Colcher A, Horn S, Golbe LI.

Mov Disord. 2010 Apr 30;25(6):665-71. doi: 10.1002/mds.23071. Review.

PMID:
20437535
20.

Early diagnosis of progressive supranuclear palsy: bucking the odds.

Golbe LI.

Neurology. 2008 Nov 25;71(22):1754-5. doi: 10.1212/01.wnl.0000338701.59007.ee. No abstract available.

PMID:
19029515
21.

The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study.

Latourelle JC, Sun M, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts RL, Guttman M, Racette BA, Perlmutter JS, Ahmed A, Shill HA, Singer C, Goldwurm S, Pezzoli G, Zini M, Saint-Hilaire MH, Hendricks AE, Williamson S, Nagle MW, Wilk JB, Massood T, Huskey KW, Laramie JM, DeStefano AL, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH.

BMC Med. 2008 Nov 5;6:32. doi: 10.1186/1741-7015-6-32.

22.

Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study.

McNicoll CF, Latourelle JC, MacDonald ME, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts RL, Guttman M, Racette BA, Perlmutter JS, Ahmed A, Shill HA, Singer C, Saint-Hilaire MH, Massood T, Huskey KW, DeStefano AL, Gillis T, Mysore J, Goldwurm S, Pezzoli G, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-Hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH.

Mov Disord. 2008 Aug 15;23(11):1596-601. doi: 10.1002/mds.22186.

23.

The epidemiology of progressive supranuclear palsy.

Golbe LI.

Handb Clin Neurol. 2008;89:457-9. doi: 10.1016/S0072-9752(07)01242-0. No abstract available.

PMID:
18631768
24.

Replication of association between ELAVL4 and Parkinson disease: the GenePD study.

DeStefano AL, Latourelle J, Lew MF, Suchowersky O, Klein C, Golbe LI, Mark MH, Growdon JH, Wooten GF, Watts R, Guttman M, Racette BA, Perlmutter JS, Marlor L, Shill HA, Singer C, Goldwurm S, Pezzoli G, Saint-Hilaire MH, Hendricks AE, Gower A, Williamson S, Nagle MW, Wilk JB, Massood T, Huskey KW, Baker KB, Itin I, Litvan I, Nicholson G, Corbett A, Nance M, Drasby E, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Al-Hinti J, Moller AT, Ostergaard K, Sherman SJ, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH.

Hum Genet. 2008 Aug;124(1):95-9. doi: 10.1007/s00439-008-0526-4. Epub 2008 Jun 29.

25.

Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study.

Tobin JE, Latourelle JC, Lew MF, Klein C, Suchowersky O, Shill HA, Golbe LI, Mark MH, Growdon JH, Wooten GF, Racette BA, Perlmutter JS, Watts R, Guttman M, Baker KB, Goldwurm S, Pezzoli G, Singer C, Saint-Hilaire MH, Hendricks AE, Williamson S, Nagle MW, Wilk JB, Massood T, Laramie JM, DeStefano AL, Litvan I, Nicholson G, Corbett A, Isaacson S, Burn DJ, Chinnery PF, Pramstaller PP, Sherman S, Al-hinti J, Drasby E, Nance M, Moller AT, Ostergaard K, Roxburgh R, Snow B, Slevin JT, Cambi F, Gusella JF, Myers RH.

Neurology. 2008 Jul 1;71(1):28-34. doi: 10.1212/01.wnl.0000304051.01650.23. Epub 2008 May 28.

26.

A clinical rating scale for progressive supranuclear palsy.

Golbe LI, Ohman-Strickland PA.

Brain. 2007 Jun;130(Pt 6):1552-65. Epub 2007 Apr 2.

PMID:
17405767
27.

An 81-year-old man with imbalance and memory impairment.

Golbe LI, Boeve BF, Keegan BM, Parisi JE.

Neurology. 2007 Apr 3;68(14):1147-52. No abstract available.

PMID:
17404198
28.

Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms.

Melquist S, Craig DW, Huentelman MJ, Crook R, Pearson JV, Baker M, Zismann VL, Gass J, Adamson J, Szelinger S, Corneveaux J, Cannon A, Coon KD, Lincoln S, Adler C, Tuite P, Calne DB, Bigio EH, Uitti RJ, Wszolek ZK, Golbe LI, Caselli RJ, Graff-Radford N, Litvan I, Farrer MJ, Dickson DW, Hutton M, Stephan DA.

Am J Hum Genet. 2007 Apr;80(4):769-78. Epub 2007 Mar 8.

29.

Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: the GenePD Study.

Wilk JB, Tobin JE, Suchowersky O, Shill HA, Klein C, Wooten GF, Lew MF, Mark MH, Guttman M, Watts RL, Singer C, Growdon JH, Latourelle JC, Saint-Hilaire MH, DeStefano AL, Prakash R, Williamson S, Berg CJ, Sun M, Goldwurm S, Pezzoli G, Racette BA, Perlmutter JS, Parsian A, Baker KB, Giroux ML, Litvan I, Pramstaller PP, Nicholson G, Burn DJ, Chinnery PF, Vieregge P, Slevin JT, Cambi F, MacDonald ME, Gusella JF, Myers RH, Golbe LI.

Neurology. 2006 Dec 26;67(12):2206-10.

PMID:
17190945
30.

Glutathione S-transferase polymorphisms and onset age in alpha-synuclein A53T mutant Parkinson's disease.

Golbe LI, Di Iorio G, Markopoulou K, Athanassiadou A, Papapetropoulos S, Watts RL, Vance JM, Bonifati V, Williams TA, Spychala JR, Stenroos ES, Johnson WG.

Am J Med Genet B Neuropsychiatr Genet. 2007 Mar 5;144B(2):254-8.

PMID:
17034008
31.

Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study.

Sun M, Latourelle JC, Wooten GF, Lew MF, Klein C, Shill HA, Golbe LI, Mark MH, Racette BA, Perlmutter JS, Parsian A, Guttman M, Nicholson G, Xu G, Wilk JB, Saint-Hilaire MH, DeStefano AL, Prakash R, Williamson S, Suchowersky O, Labelle N, Growdon JH, Singer C, Watts RL, Goldwurm S, Pezzoli G, Baker KB, Pramstaller PP, Burn DJ, Chinnery PF, Sherman S, Vieregge P, Litvan I, Gillis T, MacDonald ME, Myers RH, Gusella JF.

Arch Neurol. 2006 Jun;63(6):826-32.

PMID:
16769863
32.

BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study.

Karamohamed S, Latourelle JC, Racette BA, Perlmutter JS, Wooten GF, Lew M, Klein C, Shill H, Golbe LI, Mark MH, Guttman M, Nicholson G, Wilk JB, Saint-Hilaire M, DeStefano AL, Prakash R, Tobin S, Williamson J, Suchowersky O, Labell N, Growdon BN, Singer C, Watts R, Goldwurm S, Pezzoli G, Baker KB, Giroux ML, Pramstaller PP, Burn DJ, Chinnery P, Sherman S, Vieregge P, Litvan I, Gusella JF, Myers RH, Parsian A.

Neurology. 2005 Dec 13;65(11):1823-5.

PMID:
16344533
33.

HS1-BP3 gene variant is common in familial essential tremor.

Higgins JJ, Lombardi RQ, Pucilowska J, Jankovic J, Golbe LI, Verhagen L.

Mov Disord. 2006 Mar;21(3):306-9.

PMID:
16211613
34.

Absence of previously reported variants in the SCNA (G88C and G209A), NR4A2 (T291D and T245G) and the DJ-1 (T497C) genes in familial Parkinson's disease from the GenePD study.

Karamohamed S, Golbe LI, Mark MH, Lazzarini AM, Suchowersky O, Labelle N, Guttman M, Currie LJ, Wooten GF, Stacy M, Saint-Hilaire M, Feldman RG, Liu J, Shoemaker CM, Wilk JB, DeStefano AL, Latourelle JC, Xu G, Watts R, Growdon J, Lew M, Waters C, Vieregge P, Pramstaller PP, Klein C, Racette BA, Perlmutter JS, Parsian A, Singer C, Montgomery E, Baker K, Gusella JF, Herbert A, Myers RH.

Mov Disord. 2005 Sep;20(9):1188-91.

PMID:
15966003
35.

Woman with a 26-year history of parkinsonism, supranuclear ophthalmoplegia, and loss of postural reflexes.

Gordon PH, Fahn S, Chin S, Golbe LI, Lynch T, Eidelberg D.

Mov Disord. 2004 Aug;19(8):950-61.

PMID:
15300663
36.

Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.

Kotzbauer PT, Giasson BI, Kravitz AV, Golbe LI, Mark MH, Trojanowski JQ, Lee VM.

Exp Neurol. 2004 Jun;187(2):279-88.

PMID:
15144854
37.

Alpha-synuclein in Parkinson's disease: light from two new angles.

Golbe LI, Mouradian MM.

Ann Neurol. 2004 Feb;55(2):153-6. No abstract available.

PMID:
14755715
38.

A haplotype at the PARK3 locus influences onset age for Parkinson's disease: the GenePD study.

Karamohamed S, DeStefano AL, Wilk JB, Shoemaker CM, Golbe LI, Mark MH, Lazzarini AM, Suchowersky O, Labelle N, Guttman M, Currie LJ, Wooten GF, Stacy M, Saint-Hilaire M, Feldman RG, Sullivan KM, Xu G, Watts R, Growdon J, Lew M, Waters C, Vieregge P, Pramstaller PP, Klein C, Racette BA, Perlmutter JS, Parsian A, Singer C, Montgomery E, Baker K, Gusella JF, Fink SJ, Myers RH, Herbert A; GenePD study.

Neurology. 2003 Dec 9;61(11):1557-61.

PMID:
14663042
39.

Initiation and synergistic fibrillization of tau and alpha-synuclein.

Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM.

Science. 2003 Apr 25;300(5619):636-40.

40.

Alpha-synuclein and Parkinson's disease.

Golbe LI.

Adv Neurol. 2003;91:165-74. Review. No abstract available.

PMID:
12442675
41.

Neurodegeneration in the age of molecular biology.

Golbe LI.

BMJ. 2002 Jun 22;324(7352):1467-8. No abstract available.

42.

Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred.

Duda JE, Giasson BI, Mabon ME, Miller DC, Golbe LI, Lee VM, Trojanowski JQ.

Acta Neuropathol. 2002 Jul;104(1):7-11. Epub 2002 Apr 27.

PMID:
12070658
43.

Segregation analysis of Parkinson disease revealing evidence for a major causative gene.

Maher NE, Currie LJ, Lazzarini AM, Wilk JB, Taylor CA, Saint-Hilaire MH, Feldman RG, Golbe LI, Wooten GF, Myers RH.

Am J Med Genet. 2002 May 1;109(3):191-7.

PMID:
11977177
44.

PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study.

DeStefano AL, Lew MF, Golbe LI, Mark MH, Lazzarini AM, Guttman M, Montgomery E, Waters CH, Singer C, Watts RL, Currie LJ, Wooten GF, Maher NE, Wilk JB, Sullivan KM, Slater KM, Saint-Hilaire MH, Feldman RG, Suchowersky O, Lafontaine AL, Labelle N, Growdon JH, Vieregge P, Pramstaller PP, Klein C, Hubble JP, Reider CR, Stacy M, MacDonald ME, Gusella JF, Myers RH.

Am J Hum Genet. 2002 May;70(5):1089-95. Epub 2002 Mar 27.

45.

Epidemiologic study of 203 sibling pairs with Parkinson's disease: the GenePD study.

Maher NE, Golbe LI, Lazzarini AM, Mark MH, Currie LJ, Wooten GF, Saint-Hilaire M, Wilk JB, Volcjak J, Maher JE, Feldman RG, Guttman M, Lew M, Waters CH, Schuman S, Suchowersky O, Lafontaine AL, Labelle N, Vieregge P, Pramstaller PP, Klein C, Hubble J, Reider C, Growdon J, Watts R, Montgomery E, Baker K, Singer C, Stacy M, Myers RH.

Neurology. 2002 Jan 8;58(1):79-84. Erratum in: Neurology. 2002 Apr 9;58(7):1136.

PMID:
11781409
46.

Progressive Supranuclear Palsy.

Golbe LI.

Curr Treat Options Neurol. 2001 Nov;3(6):473-477.

PMID:
11581524
47.

Genome-wide scan for Parkinson's disease: the GenePD Study.

DeStefano AL, Golbe LI, Mark MH, Lazzarini AM, Maher NE, Saint-Hilaire M, Feldman RG, Guttman M, Watts RL, Suchowersky O, Lafontaine AL, Labelle N, Lew MF, Waters CH, Growdon JH, Singer C, Currie LJ, Wooten GF, Vieregge P, Pramstaller PP, Klein C, Hubble JP, Stacy M, Montgomery E, MacDonald ME, Gusella JF, Myers RH.

Neurology. 2001 Sep 25;57(6):1124-6.

PMID:
11571351
48.

The tau A0 allele in Parkinson's disease.

Golbe LI, Lazzarini AM, Spychala JR, Johnson WG, Stenroos ES, Mark MH, Sage JI.

Mov Disord. 2001 May;16(3):442-7.

PMID:
11391737
49.

Biochemical analysis of cybrids expressing mitochondrial DNA from Contursi kindred Parkinson's subjects.

Swerdlow RH, Parks JK, Cassarino DS, Binder DR, Bennett JP Jr, Di Iorio G, Golbe LI, Parker WD Jr.

Exp Neurol. 2001 Jun;169(2):479-85.

PMID:
11358461
50.

Pathology of PD in monozygotic twins with a 20-year discordance interval.

Dickson D, Farrer M, Lincoln S, Mason RP, Zimmerman TR Jr, Golbe LI, Hardy J.

Neurology. 2001 Apr 10;56(7):981-2. No abstract available.

PMID:
11294946

Supplemental Content

Loading ...
Support Center